Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin and Lipiodol in Hepatocellular Carcinoma (LIDA-BII)
NCT03727633Phase 2Terminated
- Sponsor
- CHU Montpellier
- Start
- Jul 2018
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of idarubicin in hepatocellular carcinoma (HCC), sponsored by CHU Montpellier. Started Jul 2018; status: terminated.
02
Drugs
idarubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03727633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03727633.